Nanoparticles as contrast agents for in-vivo bioimaging: current status and future perspectives

Abstract

Nanoparticle-based contrast agents are quickly becoming valuable and potentially transformative tools for enhancing medical diagnostics for a wide range of in-vivo imaging modalities. Compared with conventional molecular-scale contrast agents, nanoparticles (NPs) promise improved abilities for in-vivo detection and potentially enhanced targeting efficiencies through longer engineered circulation times, designed clearance pathways, and multimeric binding capacities. However, NP contrast agents are not without issues. Difficulties in minimizing batch-to-batch variations and problems with identifying and characterizing key physicochemical properties that define the in-vivo fate and transport of NPs are significant barriers to the introduction of new NP materials as clinical contrast agents. This manuscript reviews the development and application of nanoparticles and their future potential to advance current and emerging clinical bioimaging techniques. A focus is placed on the application of solid, phase-separated materials, for example metals and metal oxides, and their specific application as contrast agents for in-vivo near-infrared fluorescence (NIRF) imaging, magnetic resonance imaging (MRI), positron emission tomography (PET), computed tomography (CT), ultrasound (US), and photoacoustic imaging (PAI). Clinical and preclinical applications of NPs are identified for a broad spectrum of imaging applications, with commentaries on the future promise of these materials. Emerging technologies, for example multifunctional and theranostic NPs, and their potential for clinical advances are also discussed.

Enhanced detection of myeloperoxidase activity in deep tissues through luminescent excitation of near-infrared nanoparticles

“…The long-term toxicity of these particles to both animals and humans remains unknown. Nevertheless, concerns regarding cadmium toxicity have led to the recent development of cadmium-free quantum dots 31 and gold-based nanomaterials 32 . The prospect of applying the nanoparticle-based luminescent detection method in the clinic may draw more research to this area.…”

Functionalized nanomaterials: their use as contrast agents in bioimaging: mono- and multimodal approaches

“…A way to solve this problem relies in the synthesis of Gdbased paramagnetic NPs [68] , such as Ln 2 O 3 , GdF 3 , and GdPO 4 [26,69,70] , which yield high magnetic moments because of the abundance of paramagnetic ions on their surfaces.…”

“…Common isotopes that can be chelated onto or incorporated within NPs (in an analogous way to the gadolinium ions used for MRI) include 18 F, 11 C, 15 O, 13 N, 64 Cu, 124 I, 68 Ga, 82 Rb, and 86 Y. PET imaging using 18 F, which is the most widespread radionuclide probe used in this field, has become an established clinical tool for whole-body imaging.…”

Aptamer-Nanoparticle Bioconjugates for Drug Delivery

“…NMR) to specific molecular imaging (e.g. Fluorescence) are available and they are envisioned to be on the focus for developing cancer diagnosis, drug delivery, guided stem cell therapies, imaging of gene expression to monitor disease development, gene therapy, image guided surgery (Hahn et al, 2011). Nanoparticles for bioimaging should fullfill several requirements; being dispersable and stable in vivo, low non-specific binding, and high selectivity for their targets.…”